DRUG enters its August 20 earnings event with one of the more striking positioning shifts in recent weeks: short sellers have cut their exposure by more than 70% over the past month.
Short interest has collapsed from roughly 16,000 shares in early July to just 1,230 shares — less than 0.02% of the free float. That makes this one of the least-shorted names in the psychedelic biotech space heading into the print. The lending market tells the same story: borrow availability is extremely loose at 548%, meaning there are more than five shares available to lend for every one currently out on loan. Cost to borrow has eased to 1.73%, down about 27% over the past week. There is no short-side pressure worth discussing here.
The more interesting angle is the ownership picture. Several specialist healthcare funds initiated or materially expanded positions in the March quarter. Vestal Point Capital entered with 492,000 shares. Deerfield Management took 283,000 shares. RA Capital Management added 265,000 shares. Great Point Partners initiated 220,000 shares. Braidwell LP added 215,000 shares in the same period. Janus Henderson remains the largest institutional holder with 13.1% of shares. That cluster of healthcare-specialist buyers is a meaningful signal for a name of this size. Against that, Cormorant Asset Management trimmed 109,000 shares in late April — a notable reduction from a fund that had been a cornerstone holder — and the COO sold small tranches around the same time. CEO Ian McDonald bought 1,625 shares in June at CAD 61, well below the current price of CAD 108, though the value was modest.
The stock is up roughly 0.7% on the session but has pulled back about 4.5% over the past week, sitting near flat for the month. Past earnings prints have been broadly positive: the stock gained around 10.8% on the day following the May report, and added nearly 8% after the February event, with five-day returns of roughly 16% and 16% respectively. The most recent filing on August 14 produced a mild 1.4% decline. Peers have been mixed on the week — ZYME gained 6.7%, DNTH added 6.5%, while COGT fell 10.5% and ICCC dropped 8.6% — offering no clear sector-level tailwind or headwind.
For a pre-revenue clinical-stage biotech carrying negative earnings multiples, the August 20 print is less about financial results and more about pipeline progression: whether the company can sustain the momentum that drew a wave of specialist healthcare capital earlier this year, and whether that institutional conviction holds after Cormorant's partial exit.
See the live data behind this article on ORTEX.
Open DRUG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
